Positive Results for TYSABRI
Two-year data from the AFFIRM Phase III monotherapy trial presented for the first time, showed that treatment with TYSBARI (natalizumab)…
Part of the
network
network
Tag: natalizumab
Elan and Biogen Suspend Marketeing of TYSABRI
Elan and Biogen Idec's ongoing safety evaluation of TYSABRI has led to a previously diagnosed case of malignant astrocytoma being…
